IgA vasculitis during secukinumab therapy

Psoriatic arthritis is a chronic, seronegative spondyloarthropathy associated with psoriasis, depending on patient presentation treatment options range from non-pharmacologic measures to NSAIDs, DMARDs, and biologics. Secukinumab is a human monoclonal antibody that specifically targets interleukin-17 and has been shown to be highly effective in the treatment of psoriatic arthritis. As the use of IL-17 inhibitors has been approved in the treatment of psoriatic arthritis, clinicians need to be aware of unusual adverse events not previously observed in clinical trials. We report a rare case of Henoch-Schonlein purpura vasculitis induced by secukinumab in a 39-year-old patient. Therefore, using biologic drugs in clinical practice should be aware that cutaneous vasculitis may be triggered by anti-IL17 treatment, and early diagnosis always helps to decrease morbidity and reduce the amount of time to recovery as well as the impact on the quality of life disruption.

Automated summary

Psoriatic arthritis, a chronic seronegative spondyloarthropathy associated with psoriasis, is treated with various options ranging from non-pharmacologic measures to biologics. Secukinumab, a human monoclonal antibody targeting interleukin-17, has shown high effectiveness in treating this condition. However, clinicians should be aware of potential rare adverse events, such as Henoch-Schonlein purpura vasculitis, that may be induced by anti-IL17 treatment.